A detailed history of Amundi transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Amundi holds 3,839 shares of RCKT stock, worth $70,867. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,839
Previous 3,839 -0.0%
Holding current value
$70,867
Previous $103,000 20.39%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$16.78 - $31.94 $13,642 - $25,967
-813 Reduced 17.48%
3,839 $115,000
Q2 2023

Aug 14, 2023

SELL
$16.59 - $23.6 $12,724 - $18,101
-767 Reduced 14.15%
4,652 $92,000
Q4 2022

Feb 14, 2023

BUY
$15.5 - $22.76 $23,777 - $34,913
1,534 Added 39.49%
5,419 $106,000
Q3 2022

Nov 14, 2022

BUY
$12.37 - $18.41 $48,057 - $71,522
3,885 New
3,885 $67,000
Q1 2022

May 16, 2022

SELL
$13.16 - $23.68 $50,481 - $90,836
-3,836 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$39.41 - $47.25 $151,176 - $181,251
3,836 New
3,836 $170,000

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $1.4B
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track Amundi Portfolio

Follow Amundi and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

News

Stay updated on Amundi with notifications on news.